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Abstract
AKT-mTOR and androgen receptor (AR) signaling pathways are
aberrantly activated in prostate cancer due to frequent PTEN dele-
tions or SPOP mutations. A clinical barrier is that targeting one of
them often activates the other. Here, we demonstrate that HDAC3
augments AKT phosphorylation in prostate cancer cells and its
overexpression correlates with AKT phosphorylation in patient
samples. HDAC3 facilitates lysine-63-chain polyubiquitination and
phosphorylation of AKT, and this effect is mediated by AKT
deacetylation at lysine 14 and 20 residues and HDAC3 interaction
with the scaffold protein APPL1. Conditional homozygous deletion
of Hdac3 suppresses prostate tumorigenesis and progression by
concomitant blockade of AKT and AR signaling in the Pten knock-
out mouse model. Pharmacological inhibition of HDAC3 using a
selective HDAC3 inhibitor RGFP966 inhibits growth of both PTEN-
deficient and SPOP-mutated prostate cancer cells in culture,
patient-derived organoids and xenografts in mice. Our study identi-
fies HDAC3 as a common upstream activator of AKT and AR signal-
ing and reveals that dual inhibition of AKT and AR pathways is
achievable by single-agent targeting of HDAC3 in prostate cancer.
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Introduction
The majority of prostate cancers are dependent on androgens and
activation of the androgen receptor (AR) for growth and survival,
and androgen deprivation therapy remains the mainstay of treat-
ment for advanced prostate cancer (Watson et al, 2015). The PI3K/
AKT pathway is often aberrantly activated due to frequent deletion
or mutation of the PTEN tumor suppressor gene and activation
mutations in PIK3CA and AKT1 genes during prostate tumorigenesis
and progression (Cancer Genome Atlas Research Network, 2015,
Robinson et al, 2015), representing another key actionable target.
However, both patient data analysis and pre-clinical animal model
studies invariably show that loss of PTEN promotes enhanced AKT
activity and reduced AR signaling and that inhibition of AKT results
in AR activation while blockade of AR function increases AKT activ-
ities (Carver et al, 2011; Mulholland et al, 2011), stressing the
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requirement of co-targeting of both pathways for effective treatment
of prostate cancer.
HDACs belong to a super family of proteins. In humans, there
are 18 HDAC proteins categorized into four distinct classes (I, II, III,
and IV) according to their homology to yeast proteins, subcellular
location, and enzymatic activities (de Ruijter et al, 2003; Gallinari
et al, 2007). The HDAC family was originally found to be involved
in deacetylating the histone core of nucleosomes to configure chro-
mosomal structure and regulate gene expression (Taunton et al,
1996). Also, it is implicated in regulating deacetylation and phos-
phorylation of non-histone proteins (Kouzarides, 2000; Kramer
et al, 2009). In fact, HDAC inhibitors (HDACIs) have been devel-
oped for cancer therapy (Dokmanovic et al, 2007), supporting the
critical oncogenic role of HDACs in tumorigenesis.
HDAC3, a class I HDAC, plays critical roles in S phase progres-
sion, DNA damage control, maintenance of genomic stability, and
T-cell development (Bhaskara et al, 2008, 2010; Wang et al, 2015).
HDAC3 is overexpressed in a majority of prostate cancers (Weichert
et al, 2008), implying a role of HDAC3 in prostate tumorigenesis.
Depletion of HDAC3 or other HDACs suppresses expression of AR
and its downstream target genes in prostate cancer cells, although
the underlying mechanism remains poorly understood (Welsbie
et al, 2009). Additionally, it has been shown that HDAC3 knock-
down dramatically reduces leukemia and lymphoma cell prolifera-
tion (Matthews et al, 2015). These data suggest that HDAC3 could
be a therapeutic target for cancers such as those in the prostate.
Speckle-type POZ protein (SPOP) is the substrate-binding adaptor
of the CULLIN3-RBX1 E3 ubiquitin ligase complex (Zhuang et al,
2009). The gene encoding SPOP is the most frequently mutated gene
in human primary prostate cancers (Barbieri et al, 2012; Cancer
Genome Atlas Research Network, 2015). Functional studies show
that ectopic expression of the most frequent SPOP-mutant F133V in
human prostatic cells or knock-in in the mouse prostate results in
aberrant activation of AR and AKT-mTORC1 signaling (An et al,
2014, 2015; Geng et al, 2014; Blattner et al, 2017; Zhang et al,
2017). Most importantly, the Cancer Genome Atlas (TCGA) data
demonstrate that SPOP-mutated prostate cancers exhibit the highest
AR activity among all molecular subtypes of prostate cancer exam-
ined (Cancer Genome Atlas Research Network, 2015). Thus, it is
important to identify a common target to inhibit both AKT-mTORC1
and AR signaling in SPOP-mutated prostate cancer.
In the present study, we demonstrated that HDAC3 is required
for AKT phosphorylation in prostate cancer cells. Prostate-specific
knockout of Hdac3 decreased Akt phosphorylation, alleviated the
tumor burden, and ultimately prolonged survival of Pten knockout
mice. In human prostate cancer organoids and xenograft models,
we further showed that a selective HDAC3 inhibitor is efficacious in
inhibition of AKT and AR signaling in both PTEN- and SPOP-mutant
background.
Results
HDAC3 is the only class I/II HDAC protein that regulates
AKT phosphorylation
It has been shown previously that different pan class I/II HDACIs
have differential effects on AKT phosphorylation at both threonine
308 (T308) and serine 473 (S473) in AR-negative prostate cancer
PC-3 cells (Chen et al, 2005a). By treating AR-positive prostate
cancer C4-2 cells with the commonly used pan class I/II HDACIs
trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA),
panobinostat (LBH589), and HDAC6-selective inhibitor tubastatin A,
we demonstrated that these pan class I/II HDACIs, but not tubas-
tatin A completely inhibited AKT phosphorylation at S473 and T308
(Fig 1A). To further clarify whether this was due to the possibility
that these HDACIs potentially regulate the expression of upstream
regulators (e.g., CXCR7 or PHLPP1) (Wang et al, 2008; Luan et al,
2009; Bradley et al, 2013), and thereby indirectly affect AKT phos-
phorylation, we treated C4-2 cells with cycloheximide (CHX) to
block de novo protein synthesis. To our surprise, CHX treatment
only had very minimal effect on pan HDACI-induced inhibition of
AKT phosphorylation (Fig 1A), suggesting that decreased AKT phos-
phorylation by pan class I/II HDACIs was not primarily mediated by
their effect on expression of AKT upstream regulators.
To identify which member(s) in the class I/II HDAC family is the
major modulator of AKT phosphorylation, all 11 members in these
subfamilies were knocked down individually by two independent
small hairpin RNAs (shRNAs). Each HDAC gene was effectively
knocked down to 40% or more at mRNA level (Fig 1B). Notably,
only HDAC3 knockdown substantially decreased AKT phosphoryla-
tion at both T308 and S473 residues in a similar degree in C4-2 cells
(Fig 1C). We also examined the effect of a selective HDAC3 inhi-
bitor, RGFP966, on AKT phosphorylation. We demonstrated that
RGFP966 inhibited AKT phosphorylation as early as 0.5 h post-treat-
ment (Fig 1D), further suggesting a direct effect of HDAC3 inhibition
of AKT phosphorylation. Together, these data indicate that HDAC3,
but not other class I/II HDACs, is primarily required for AKT phos-
phorylation in this cell line.
Consistent with a previous finding that class I HDAC members
(HDAC1, 2, 3, and 8) are highly expressed in prostate cancers
(Weichert et al, 2008), analysis of TCGA data also showed that
expression of these four HDAC genes was upregulated at the mRNA
level in tumors compared to normal tissues (Fig EV1A). Specifically,
comparison of 52 paired normal and tumor samples showed that
the majority of them [approximately 56% (29 out of 52)] exhibited
an increased expression of HDAC3 at the mRNA level in tumors
(Fig EV1B), suggesting that HDAC3 is a highly relevant protein in
prostate cancer. We further examined the correlation between
HDAC3 protein expression and AKT phosphorylation by performing
immunohistochemistry (IHC) on a tissue microarray (TMA) contain-
ing 55 prostate cancer samples. We demonstrated that increased
expression of HDAC3 correlated with higher levels of AKT phospho-
rylation (S473) in this cohort of patients (Fig 1E and F). Therefore,
HDAC3 might be an essential upstream regulator of AKT phosphory-
lation in prostate cancer cells in culture and in patients.
HDAC3 is required for growth factor-induced AKT
polyubiquitination and activation
Polyubiquitination is a critical step for growth factor-induced phos-
phorylation and activation of AKT (Yang et al, 2009). Given that
acetylation and polyubiquitination can compete with each other by
occurring at the same lysine residues (Yang & Seto, 2008), we inves-
tigated whether HDAC3 regulates AKT acetylation and polyubiquiti-
nation. Firstly, we showed that HDAC3 overexpression substantially
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Figure 1. HDAC3 regulates AKT phosphorylation.
A HDACIs inhibited AKT phosphorylation. C4-2 cells were pre-treated with 20 lM of CHX for 30 min followed by treatment with pan HDACIs TSA (1 lM), SAHA (5 lM),
LBH589 (0.1 lM), or a HDAC6 selective inhibitor Tuba (5 lM) for 24 h prior to Western blot analysis with indicated antibodies. The efficacy of CHX was evident by
blockade of induction of FBP1 expression by HDACIs as reported (Yang et al, 2017).
B The knockdown efficiency of each member of class I/II HDACs by shRNAs. C4-2 cells were stably infected with control or gene-specific shRNAs for 4 days and
harvested for RT–qPCR. Expression of each gene was first normalized to the level of GAPDH, and then the expression level of each gene in gene knockdown cells was
normalized by that in control knockdown cells. The shRNA knockdown efficiency was determined by subtracting the normalized value from 100%. Data represents
means  SEM. The RT–qPCR was performed in triplicate for each sample.
C Control or gene-specific knockdown C4-2 cells were serum starved for 24 h and then cultured in regular culture medium for 12 h followed by Western blots for
indicated proteins. Western blot bands for total and phosphorylated AKT were quantified and normalized to the quantified values of b-Tubulin (loading control). The
normalized values were further normalized to the value of shC-infected cells without serum stimulation.
D C4-2 cells were treated with vehicle (DMSO) or HDAC3 inhibitor RGFP966, and at different time points, cells were harvested for Western blots with the indicated
antibodies.
E The representatives of IHC staining for HDAC3 and AKT S473 phosphorylation in prostate cancer patient specimens; scale bar: 50 lm; scale bar for the inset: 20 lm.
F Correlation between expression of AKT S473 phosphorylation and HDAC3 was shown, n = 55, ***P = 1.87e-07 was performed by Pearson’s product-moment
correlation test.
Source data are available online for this figure.
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decreased AKT acetylation without affecting total AKT level in C4-2
cells (Fig 2A). Decreased AKT acetylation was accompanied with
increased polyubiquitination of AKT, and the effect was dose-depen-
dent (Fig 2B). In agreement with the observation that HDAC3
knockdown decreased AKT phosphorylation (Fig 1C), overexpres-
sion of HDAC3 increased AKT phosphorylation at both T308 and
S473 sites (Fig 2C). In contrast, depletion of HDAC3 by a pool of
three independent siRNAs increased AKT acetylation (Fig 2D), but
decreased AKT polyubiquitination and phosphorylation (Fig 2D and
E). The HDAC3 inhibitor RGFP966 also undermined AKT ubiquitina-
tion (Fig 2F).
Growth factors, such as insulin-like growth factor-1 (IGF-1) and
epidermal growth factor (EGF), are the potent upstream stimulators






Figure 2. HDAC3 is important for growth factor-induced AKT deacetylation and polyubiquitination.
A 293T cells were transfected with plasmids for Flag-HDAC3 and Myc-AKT followed by IP and Western blots with the indicated antibodies.
B C4-2 cells were transfected with plasmids for Myc-AKT, HA-Ub, and Flag-HDAC3 (different doses) for 24 h followed by IP and Western blots with the indicated
antibodies.
C C4-2 cells were transfected with plasmids for Myc-AKT and Flag-HDAC3 (different doses) for 24 h followed by Western blots with the indicated antibodies.
D, E C4-2 cells were transfected with a pool of control or HDAC3-specific siRNAs for 48 h followed by IP and/or Western blots with the indicated antibodies.
F C4-2 cells were transfected with HA-Ub plasmids and treated with 3 lM of RGFP966 for 24 h followed by IP and/or Western blots with the indicated antibodies.
G C4-2 cells were treated with 10 ng/ml of IGF-1 for different periods of time and harvested for IP and Western blots with the indicated antibodies.
H, I C4-2 cells were transfected with a pool of control and HDAC3-specific siRNAs for 48 h and then treated with IGF-1 (H) or EGF (I) followed by Western blots for
indicated proteins.
Data information: The asterisk (*) indicates the specific HDAC3 protein band.
Source data are available online for this figure.
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To examine whether growth factor stimulation affects AKT acetyla-
tion, we treated C4-2 cells with IGF-1 and found that AKT acetyla-
tion was inhibited by IGF-1 in a dose-dependent manner, while its
phosphorylation at both T308 and S473 was concomitantly upregu-
lated (Fig 2G). These data further confirmed that AKT phosphoryla-
tion is negatively regulated by its acetylation. Most importantly,
knockdown of HDAC3 abolished IGF-1-induced elevation of AKT
phosphorylation (Fig 2H). Similar to IGF-1, EGF is another well-
known growth factor that activates the PI3K/AKT signaling path-
way. Similarly, we found that AKT phosphorylation at T308 and
S473 sites was enhanced by EGF treatment in a time-dependent
manner, but the magnitude of AKT activation was substantially
diminished in HDAC3 knockdown cells (Fig 2I). Our data show that
HDAC3 is required for growth factor-stimulated phosphorylation of
AKT.
A functional AKT-binding domain is identified in HDAC3
To understand the molecular mechanisms by which HDAC3 regu-
lates acetylation, polyubiquitination, and phosphorylation of AKT,
we examined whether HDAC3 interacts with AKT. Reciprocal co-
immunoprecipitation (co-IP) assays showed that both ectopically
expressed and endogenous HDAC3 and AKT proteins were detect-
able in the same protein complex in 293T and C4-2 cell lines,
respectively (Fig 3A–C). In contrast, consistent with the unbiased
screening results (Fig 1B and C), endogenous AKT did not interact
with endogenous HDAC1 and HDAC2 in C4-2 cells (Fig 3D).
To identify the specific region of HDAC3 that is essential for AKT
binding, we generated four glutathione-S-transferase (GST)-HDAC3
recombinant proteins (P1, P2, P3, and P4; Fig 3E). GST pull-down
assays showed that GST-HDAC3 P2 (amino acids (aa) 101–200), but
not GST or other GST-HDAC3 recombinant proteins, specifically
interacted with Myc-tagged AKT (Fig 3F). To further narrow down
the specific fragment for AKT binding, we constructed five addi-
tional GST-HDAC3 recombinant proteins (HDAC3-D1, 2, 3, 4, and 5)
by sequentially deleting 20 amino acids from GST-HDAC3 P2 recom-
binant protein (aa 101–120, 121–140, 141–160, 161–180, and 181–
200). GST pull-down assay showed that loss of aa 141–160 in
HDAC3 completely abolished its interaction with AKT (Fig 3G), and
we termed this region as AKT-binding domain (ABD). Unlike the
wild-type HDAC3 (HDAC3-WT), expression of ABD-deletion mutant
of HDAC3 failed to inhibit AKT acetylation (Fig 3H). It also lost the
ability to increase polyubiquitination and phosphorylation of AKT
(Fig 3I and J). Furthermore, by examining more than 100 AKT-
interacting proteins, we noticed that protein sequences in the
AKT-binding region are reported only in five of them (APPL1, YB-1,
BRCA1, MEN1, and DAB2), but we found no consensus
AKT-binding sequence between these five proteins and HDAC3,
suggesting that the ABD in HDAC3 is unique. Together, our data
demonstrate that HDAC3 interacts with AKT via ABD, which is
indispensable for HDAC3-enhanced AKT phosphorylation.
HDAC3 associates with AKT in plasma membrane and
promotes lysine-63 polyubiquitination of AKT
Plasma membrane association is critical for AKT phosphorylation
and activation (Gao et al, 2011). A significant percentage of HDAC3
proteins are localized in the plasma membrane (Wen et al, 2003;
Longworth & Laimins, 2006). In concordance with our findings in
prostate cancer cells, a recent chemoresistance study showed that
HDAC3 regulates AKT phosphorylation in acute myeloid leukemia
(Long et al, 2017). Immunofluorescent cytochemistry (IFC) staining
in the same study indicated that HDAC3 and AKT interact in the
nucleus, suggesting that HDAC3 regulates AKT phosphorylation
through its nuclear function. In contrast, our confocal microscopy
analysis showed that both proteins were detectable in the plasma
membrane, cytoplasm, and nucleus of both LNCaP and C4-2 pros-
tate cancer cells (Figs 4A and EV2A). Moreover, protein fractiona-
tion assays showed that endogenous HDAC3 and AKT proteins
interacted with each other in both cytoplasmic and nuclear compart-
ments (Fig 4B). Most importantly, we demonstrated that increased
expression of HDAC3 markedly enhanced AKT association with
plasma membrane, but not in the nucleus (Fig EV2B). Furthermore,
we generated a C-terminal truncated mutant of HDAC3 [HDAC3 (1–
313)] (Fig EV2C), which has been shown to be localized mainly in
the plasma membrane and cytoplasm (Yang et al, 2002). We con-
firmed it is also the case in C4-2 cells (Fig EV2D and E). Most
importantly, ectopic expression of the HDAC3 cytoplasmic mutant
enhanced IGF-1-induced AKT phosphorylation to the extent similar
to the wild-type counterpart (Fig 4C). These data suggest that the
cytoplasmic function of HDAC3 is important for its regulation of
AKT phosphorylation.
To determine whether HDAC3 regulation of AKT acetylation
requires its deacetylase activity, we constructed HDAC3-H134Q, a
deacetylase inactivation mutant of HDAC3 (Wen et al, 2003). We
demonstrated that apart from HDAC3-WT, expression of H134Q
mutant failed to diminish AKT acetylation (Figs 3H and 4D). The
same was true for AKT polyubiquitination and phosphorylation
(Figs 3I and J, and 4E). It is worth noting that the deacetylation
enzymatic activity of HDAC3 is important for its role in regulating
gene expression. However, whether the enzymatic dead mutant
H134Q and the AKT-binding deficient mutant AKTDABD have
common or distinct effects on gene expression is unclear at present
and warrants further investigation.
Lysine residues 14 and 20 (K14 and K20) were identified as
two major acetylation sites on AKT (Pillai et al, 2014). Authors of
a recent study in leukemia cells concluded that HDAC3 activates
AKT by deacetylating AKT at K20 (Long et al, 2017). However,
data presented in the study clearly showed that expression of
K20R mutant of HDAC3 markedly increased AKT phosphorylation
at both T308 and S473 sites (Long et al, 2017), arguing the exis-
tence of additional lysine residue(s) in facilitating AKT ubiquitina-
tion and phosphorylation. Indeed, our mutagenesis studies
demonstrated that only dual acetylation-mimicking mutant of K14
and K20 (K14Q and K20Q), but not individual mutant alone,
abolished HDAC3-augmented polyubiquitination and phosphoryla-
tion of AKT in C4-2 cells (Fig 4F and G). Since lysine 63 (K63)-
chain polyubiquitination is important for membrane localization
and phosphorylation of AKT (Pickart, 2001), we examined the
effect of HDAC3 on AKT K63-chain polyubiquitination. We found
that expression of HDAC3 increased AKT polyubiquitination and
this effect was abolished by K63R-mutated Ub, but not K48R or
WT Ub (Fig 4H). These data suggest that deacetylation at both
K14 and K20 residues is important for HDAC3 regulation of AKT
phosphorylation and this effect of HDAC3 is mediated by K63-
linked polyubiquitination of AKT.
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APPL1 facilitates HDAC3-AKT interaction and AKT activation
Overexpression of the scaffold protein APPL1 stimulates insulin-
mediated AKT phosphorylation (Mao et al, 2006; Deepa & Dong,
2009), highlighting the role of APPL1 expression in insulin signal
transduction; however, its precise underlying mechanism is unclear.
We therefore sought to investigate whether APPL1 plays any role in
HDAC3 regulation of AKT. Co-IP assay demonstrated that endoge-
nous HDAC3 and APPL1 interacted with one another in C4-2 cells
(Fig 5A). GST pull-down assay further showed that the P1 fragment
(aa 1–100) of HDAC3 was specifically bound by APPL1 (Figs 3E and
5B); this is different from the ABD motif located in the P2 fragment
(Fig 3E and F). To define the specific fragment in APPL1 required
for HDAC3 binding, we constructed five GST-APPL1 recombinant
proteins corresponding to four well-studied functional domains of
APPL1. GST pull-down assays indicated that the PH domain is the
only region specifically interacting with HDAC3 (Fig 5C and D).
Although knockdown of APPL1 by siRNAs did not affect the
expression level of HDAC3 and AKT proteins (Fig 5E), it largely
diminished AKT binding with HDAC3 and AKT phosphorylation at
both T308 and S473 (Fig 5E and F). Given that HDAC3 is a key
component of the NCOR/SMRT complex, we examined the effect of
APPL1 knockdown on this complex. We demonstrated that APPL1
knockdown largely increased HDAC3 interaction with both NCOR
and SMRT (Fig EV2F), suggesting that APPL1 binding can prevent
NCOR/SMRT from binding to HDAC3. Moreover, IGF-1 stimulation
increased HDAC3 binding with AKT and APPL1 and enhanced
APPL1 binding with AKT and HDAC3 (Fig 5G and H), suggesting
that these three proteins cooperate in IGF-1 transduced signaling.
Importantly, depletion of HDAC3 by siRNAs abolished both basal
level and IGF-1-enhanced interaction between APPL1 and AKT
(Fig 5H), highlighting the importance of HDAC3 in mediating the
interaction between AKT and APPL1. Furthermore, IGF-1 stimula-
tion increased IGFR engagement with APPL1, HDAC3, and AKT
(Fig 5I). Most strikingly, silencing of APPL1 disrupted IGFR associa-
tion with AKT and HDAC3, whereas depletion of HDAC3 only
disrupted IGFR interaction with AKT, but not APPL1 (Fig 5I and J).
Based upon these findings, we envision a model in which, in the
absence of activation of IGFR by IGF-1, APPL1 and HDAC3 drift in
the cytoplasm and AKT is subject to be acetylated and thereby
immune to E3 ligase-mediated ubiquitination (Fig 5K). Upon the
stimulus of IGF-1, IGFR recruits APPL1 which in turn scaffolds the
interaction between HDAC3 and AKT and facilitates the deacetyla-
tion of AKT by HDAC3, making AKT poised for polyubiquitination,
phosphorylation, and activation (Fig 5K).
Hdac3 deletion attenuates Pten deletion-mediated
prostate tumorigenesis
Approximately 70% of prostate cancers lose one copy of PTEN gene
by the time of diagnosis (Chen et al, 2005b). PTEN loss leads to
AKT hyperactivation and prostate tumorigenesis and progression
(Majumder & Sellers, 2005; Shukla et al, 2007). As expected, AKT
phosphorylation was elevated by PTEN knockdown in PTEN-posi-
tive 22Rv1 prostate cancer cells, but PTEN loss-enhanced AKT phos-
phorylation was mitigated by HDAC3 co-knockdown (Fig 6A).
Knockdown of HDAC3 in PTEN-negative C4-2 cells decreased cell
growth in both 2-dimension (2D) and 3D cultures (Fig EV3A–E).
Confocal microscopy analysis indicated that the growth inhibitory
effect was correlated with decreased AKT phosphorylation
(Fig EV3F and G). These data indicate an important role of HDAC3
in PTEN loss-mediated AKT activation.
To extend our observation from in vitro to in vivo studies, pros-
tate-specific Pten homozygous deletion mouse model was employed.
This mouse model recapitulates prostate tumorigenesis and progres-
sion and is considered as a reliable and valuable model to study
prostate cancer (Lesche et al, 2002; Wang et al, 2003). To investi-
gate the effect of Hdac3 loss on Akt phosphorylation and associated
prostate tumorigenesis, we crossbred probasin-Cre transgenic mice
(Pb-Cre4; Wu et al, 2001) with Hdac3 conditional (Hdac3Loxp/Loxp,
Hdac3L/L; Bhaskara et al, 2008) and Pten conditional (PtenLoxp/Loxp,
PtenL/L) mice (Wang et al, 2003). A cohort of mice with four dif-
ferent genotypes were generated: prostate-specific Pten knockout
alone (Pb-Cre4; PtenL/L, hereafter termed as Ptenpc/), Pten/Hdac3
double knockout (Pb-cre4; PtenL/L;Hdac3L/L, termed as Ptenpc/;
Hdac3pc/), Hdac3 knockout alone (Pb-Cre4; Hdac3L/L, termed as
Hdac3pc/), and Cre-negative PtenL/L; Hdac3L/L control mice (ter-
med as “wild-type”).
As demonstrated by IHC, Hdac3 protein was readily detected in
the prostates of “wild-type” and Ptenpc/ mice, but little to no
Hdac3 protein was detected in the prostates of Hdac3pc/ and
Ptenpc/;Hdac3pc/ counterparts (Fig 6B-i). As expected, Pten
protein was barely detected in Ptenpc/ and Ptenpc/;Hdac3pc/
prostates, while it was readily expressed in “wild-type” and
Hdac3pc/ prostates (Fig 6B-ii). Consistent with the results of Pten
deletion in the cell culture model (Fig 6A), Akt phosphorylation
level was robustly increased in the prostates of Ptenpc/ mice
compared with Pten-positive controls, while Hdac3 loss significantly
diminished AKT phosphorylation in prostate tumors with Ptenpc/
background (Fig 6B-iii). In accordance with IHC results shown
in Fig 6B-iii, Western blot analysis also revealed that Akt
◀ Figure 3. A region (aa 141–160) in HDAC3 is indispensable for its interaction with AKT.A, B 293T cells were transfected with indicated plasmids for 24 h followed by IP and Western blots with the indicated antibodies. The asterisk (*) indicates the specific
Flag-HDAC3 protein band.
C, D C4-2 cell lysate was prepared for IP and Western blots with the indicated antibodies. The asterisk (*) indicates the specific Flag-HDAC3 protein band.
E An illustration depicts four fragments of HDAC3 protein for generation of GST recombinant proteins.
F, G C4-2 cells were transfected with Myc-tagged AKT for 24 h, and cell lysate was prepared for GST pull-down assay. Input and GST or GST-HDAC3 recombinant
proteins used for pull-down assay in (F) were examined by Ponceau S staining and pull-down proteins were evaluated by Western blot with anti-Myc antibody.
GST or GST-HDAC3 recombinant proteins used for pull-down assay in (G) were examined by Coomassie blue staining. GST or GST-HDAC3 recombinant proteins
with expected molecular mass are indicated by asterisks.
H–J C4-2 cells were transfected with indicated plasmids for 24 h followed by IP and Western blots with the indicated antibodies.
Source data are available online for this figure.
ª 2018 The Authors EMBO Molecular Medicine 10: e8478 | 2018 7 of 20







Figure 4. HDAC3 associates with AKT in plasma membrane and induces lysine 63-linked ubiquitination of AKT.
A LNCaP and C4-2 cells grown in logarithmic phase were fixed and subjected to IFC. Cell nuclei were counterstained by DAPI. Arrows point to the co-localization of
AKT and HDAC3 proteins in the plasma membrane. Approximately 80% of LNCaP cells and 85% of C4-2 cells showed the co-localization of these two proteins on
plasma membrane. Scale bars, 20 lm.
B C4-2 cells were treated with IGF-1 for 30 min and then harvested for cellular fractionation followed by IP and Western blots with the indicated antibodies.
C C4-2 cells were transfected with empty vector (EV) or HA-tagged wild-type or mutant HDAC3 for 24 h followed by treatment of 10 ng/ml IGF-1 for 30 min. Cells
were harvested for Western blots with the indicated antibodies.
D–H C4-2 cells were transfected with the indicated plasmids for 24 h and harvested for IP and Western blots with the indicated antibodies.
Source data are available online for this figure.
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phosphorylation was largely decreased in Hdac3 and Pten double
knockout tumor tissues compared to Pten single knockout tumors
(Fig 6C). Meanwhile, Akt acetylation was elevated due to Hdac3
deletion (Fig 6C), further supporting the conclusion that Hdac3 loss
undermined Akt phosphorylation by increasing its acetylation.
By following up on the survival of a cohort of 83 mice for over
12 months, we found that mice in both “wild-type” and Hdac3pc/
groups all survived (Fig 6D). Notably, three mice died in the
Ptenpc/;Hdac3pc/ group, whereas seven mice died in the
Ptenpc/ group (Fig 6D), suggesting that conditional knockout of
Hdac3 significantly prolonged the overall survival of mice with a
Ptenpc/ background. As expected, both “wild-type” and
Hdac3pc/ did not display visible tumors in the prostate, while the
prostate lobes of Ptenpc/;Hdac3pc/ mice at 4 months old were
obviously smaller than those of age-matched Ptenpc/ mice, indi-
cating Hdac3 loss delays the growth of tumors in Ptenpc/ mice
(Fig 6E and F).
Prostatic intraepithelial neoplasia (PIN) is a commonly used indi-
cator of prostate tumorigenesis in mouse models (Park et al, 2002).
We analyzed the frequency of PIN in all the lobes and found that
the majority of acini were high-grade PIN (HGPIN)/cancer in the
prostates of Ptenpc/ mice but more low-grade PIN (LGPIN) in the
Ptenpc/;Hdac3pc/ group (Fig 6F and G). Since Akt phosphoryla-
tion is associated with cell proliferation and survival (Lawlor &
Alessi, 2001), we used proliferation marker Ki67 to evaluate cell
proliferation in prostate tissues. By performing Ki-67 IHC and quan-
tifying the percentage of Ki67-positive cells, we demonstrated that
Hdac3 loss reduced the percentage of proliferative cells in Pten-defi-
cient prostates (Fig 6H and I). In contrast, cleaved caspase-3 IHC
analysis demonstrated that Hdac3 loss had no overt effect on apop-
tosis (Fig EV4A and B). These data suggest that the inhibitory effect
of Hdac3 loss on Pten deletion-induced tumorigenesis in the prostate
is primarily mediated by decreased cell proliferation, but less likely
via its effect on apoptosis. These data indicate that HDAC3 plays a
pivotal role in PTEN loss-induced AKT activation and prostate
tumorigenesis and progression.
Cell culture studies have shown previously that pharmacological
inhibition or knockdown of HDAC3 blocks AR-mediated transcrip-
tional activation of its target genes, such as TMPRSS2 and NKX3.1,
although the underlying mechanisms remain poorly understood
◀ Figure 5. The scaffold protein APPL1 facilitates HDAC3 regulation of AKT.A C4-2 cell lysate was prepared for IP and Western blots with the indicated antibodies. The asterisk (*) indicates the specific HDAC3 protein band.
B C4-2 cell lysate was prepared for GST pull-down assay using GST or GST-HDAC3 recombinant proteins (stained with Coomassie blue, low panel) followed by
Western blot with anti-APPL1 antibody (upper panel). GST or GST-HDAC3 recombinant proteins with expected molecular mass are indicated by asterisks.
C An illustration depicts four functional domains (BAR, PH, PTB, and PDZ) of APPL1 used for construction of GST-APPL1 recombinant proteins.
D C4-2 cell lysate was prepared for GST pull-down assay using GST or GST-APPL1 recombinant proteins (stained with Coomassie blue, low panel) followed by Western
blot with anti-HDAC3 antibody (upper panel). The red asterisk (*) indicates the specific HDAC3 protein band, while the black ones indicate the specific domains of
APPL1.
E, F C4-2 cells were transfected with a pool of control or APPL1-specific siRNAs for 48 h followed by IP and Western blots with the indicated antibodies. The asterisk (*)
indicates the specific HDAC3 protein band.
G C4-2 cells were treated with 10 ng/ml of IGF-1 for different periods of time followed by IP and Western blots with the indicated antibodies. The asterisk (*)
indicates the specific HDAC3 protein band.
H–J C4-2 cells were transfected with indicated siRNAs and treated with 10 ng/ml of IGF-1 for 30 min and followed by IP and Western blots with the indicated
antibodies. The asterisks (*) indicate the specific HDAC3 protein bands.
K A hypothetical model depicting roles of HDAC3 and APPL1 in growth factor (GF)-induced AKT activation. In the absence of the interaction of GF with a receptor
tyrosine kinase (RTK), HDAC3 and APPL1 drift around in the cytosol. As a result, AKT becomes highly acetylated and resistant to be polyubiquitinated. Upon GF
stimulation, RTK recruits APPL1, which in turn functions as a scaffold facilitating HDAC3-mediated deacetylation of AKT, thereby making AKT poised for further
activation by polyubiquitination. Activation of this deacetylase-dependent function of HDAC3 may also require the binding by the deacetylase activating domain of
SMRT.
Source data are available online for this figure.
▸Figure 6. Hdac3 deletion decreases AKT phosphorylation and tumor growth in Pten knockout prostate cancer.A 22Rv1 cells were transfected with a pool of control and gene-specific siRNAs for 48 h followed by Western blots with the indicated antibodies. The asterisk (*)
indicates the specific HDAC3 protein band.
B IHC for Hdac3 (i), Pten (ii) and phosphorylated Akt (p-Akt-S473) (iii) in prostate tissues of “wild-type”, Hdac3pc/, Ptenpc/, and Ptenpc/;Hdac3pc/ mice at age of
4 months. The inset is a high-magnification image of the framed area in each panel. Scale bar: 50 lm; scale bar in the inset: 10 lm.
C Protein samples were prepared from prostate tissues of Ptenpc/ and Ptenpc/;Hdac3pc/ mice at age of 4 months followed by IP and Western blots with the
indicated antibodies.
D Kaplan–Meier survival analysis of “wild-type” (n = 25), Hdac3pc/ (n = 18), Ptenpc/ (n = 15), Ptenpc/;Hdac3pc/ (n = 25) mice. The “n” indicates the number of
mice. *P = 0.012 comparing the overall survival of Ptenpc/;Hdac3pc/ mice (n = 25) with “Ptenpc/” mice (n = 15) by Gehan–Breslow–Wilcoxon test.
E Representatives of genitourinary tracts of Ptenpc/ and Ptenpc/;Hdac3pc/ mice at age of 4 months.
F Representatives of H&E staining for ventral prostate (VP) of 4-month-old mice with indicated genotypes. Scale bar: 50 lm.
G Quantification of non-malignant, low-grade PIN (LGPIN), and high-grade PIN (HGPIN)/cancer acini in the lobes of AP, VP, and DLP of the mice with the indicated
genotypes (n = 6 mice for each group).
H, I Representatives of Ki67 staining in prostate tissues from Ptenpc/ and Ptenpc/;Hdac3pc/ mice at age of 4 months are shown in (H) with the quantitative data
in (I). Scale bar: 100 lm; scale bar in the inset: 10 lm. Data are shown as means  SEM (n = 6 mice for each group); ***P = 1.64e-04 was performed by the
unpaired two-tailed Student’s t-test.
Source data are available online for this figure.
10 of 20 EMBO Molecular Medicine 10: e8478 | 2018 ª 2018 The Authors







ª 2018 The Authors EMBO Molecular Medicine 10: e8478 | 2018 11 of 20
Yuqian Yan et al AKT and AR inhibition by targeting HDAC3 EMBO Molecular Medicine
(Welsbie et al, 2009). In the Hdac3 knockout mouse prostate, we
demonstrated that homozygous deletion of Hdac3 not only
decreased Ar protein level, but also decreased expression of its
target genes including Probasin, Tmprss2, and Nkx3.1 in both wild-
type and Pten-deficient backgrounds (Fig EV4C and D). We further
showed that ectopic expression of wild-type HDAC3 increased
expression of AR target genes NXK3.1 and PSA in LNCaP cells, and
similar results were obtained in cells transfected with HDAC3 (1–
313), a C-terminal truncated mutant of HDAC3 that is localized
mainly in the plasma membrane and cytoplasm (Figs EV2D and E,
and EV4E–G). These data indicate that HDAC3 regulates AR tran-
scriptional activity in prostate cancer cells in culture and in mice
and this effect is likely mediated by its function in the cytoplasm. It
is worth noting that AR is a transcription factor which is active in
the nucleus, and therefore, it is possible that the cytosolic HDAC3
may modulate AR activity through indirect regulation of AR-regula-
tory signaling pathways.
HDAC3 inhibitor RGFP966 inhibits growth of PTEN-deficient
prostate cancer cell lines, organoids, and xenografts
Given that selective HDAC3 inhibitor RGFP966 exhibited a
pronounced anti-cancer effect in hematological malignancies
(Matthews et al, 2015), we sought to determine whether RGFP966
inhibits cell growth of solid tumors such as prostate cancer. A
Western blot-based survey was conducted to identify suitable cell
lines for study. C4-2 and 22Rv1 were selected for further analysis
because (i) both cell lines are AR-positive, (ii) both expressed simi-
lar levels of HDAC3, and (iii) one is PTEN-negative and the other is
PTEN-positive (Fig 7A). Both cell lines were treated with RGFP966
or AKT inhibitor GDC0068, an ATP-competitive pan-AKT inhibitor
that has been used for treatment of solid tumors in a phase I trial
(Saura et al, 2017). Clonogenic survival assay demonstrated that
PTEN-null C4-2 cells were more sensitive to GDC0068 compared
with PTEN-positive 22Rv1 cells (Fig 7B). This result is consistent
with a previous report that cell lines with a high level of AKT phos-
phorylation are more sensitive to GDC0068 (Lin et al, 2013), a
notion of “oncogene addiction”. On the contrary, we observed that
22Rv1 (IC50: 0.720 lM) was more sensitive to RGFP966 compared
with C4-2 (IC50: 1.19 lM) (Fig 7C), indicating that PTEN status is a
potential determinant of the efficacy of HDAC3 inhibitor in prostate
cancer treatment. Interestingly, the steep curves of the clonogenic
survival data clearly showed that both cell lines were more sensitive
to RGFP966 than GDC0068 (Fig 7B and C), suggesting that prostate
cancer cells are vulnerable to HDAC3 inhibition. Based upon these
observations, we predicted that a higher concentration of RGFP966
alone should be more efficacious in inhibition of C4-2 cell growth
than GDC0068. To test this hypothesis, we treated C4-2 cells with
GDC0068 or RGFP966 at the concentration of 1× or 2× IC50. Clono-
genic survival assay showed that the higher concentration of
RGFP966 markedly inhibited cell growth with formation of fewer
and smaller colonies, while the higher dose of GDC0068 only
slightly decreased the size and number of colonies (Fig 7D and E).
S6K and 4E-BP1 phosphorylation are two well-defined down-
stream events of AKT activation (Chung et al, 1994). We demon-
strated that S6K phosphorylation was only partially diminished by
the higher dose of GDC0068 in C4-2 cells (Fig 7F). Most strikingly,
the treatment with a higher concentration of RGFP966 totally inhib-
ited S6K phosphorylation (Fig 7F). A similar trend was observed for
4E-BP1 phosphorylation even though the inhibitory effect of
GDC0068 on 4E-BP1 phosphorylation was more pronounced than
that on S6K phosphorylation (Fig 7F). Notably, similar to previous
reports related to AKT-mTOR inhibitors (Carver et al, 2011; Mulhol-
land et al, 2011), we also found that GDC0068 treatment increased
▸Figure 7. The HDAC3 inhibitor suppresses PTEN-deficient prostate cancer growth.A Cell lysate was prepared from indicated prostate cancer cell lines for Western blot analysis. Arrows show the full length and variants of AR.
B, C C4-2 and 22Rv1 cells were treated with GDC0068 (B) and RGFP966 (C). IC50 is shown as a dotted line in the middle of the graph; for C4-2 cells, IC50 of
GDC0068 = 1.85 lM; IC50 of RGFP966 = 1.19 lM; for 22Rv1 cells, IC50 of GDC0068 = 2.67 lM; IC50 of RGFP966 = 0.72 lM. The survival curve was generated from
three independent experiments and each experiment was in triplicate. The error bars indicate the smallest and largest value among three independent
experiments, which represented by lower whisker and upper whisker, respectively.
D, E C4-2 cells were treated with low (L, 1× IC50) or high (H, 2× IC50) concentrations of GDC0068 or RGFP966 for 4 days. The number of colonies with more than 50
cells was counted. Representatives of colonies are shown in (D) with quantification data shown in (E). Data represent means  SEM; GDC (L) versus GDC (H):
*P = 0.037; GDC0068 (H) versus RGFP (H): ***P = 1.47e-05, RGFP (L) versus RGFP (H): ***P = 3.55e-05 were performed by the unpaired two-tailed Student’s t-test.
F C4-2 cells were treated with GDC0068 or RGFP966 for 24 h followed by Western blots.
G, H Representative images of 3D cultures of C4-2 cells at day 5 post-treatment of GDC0068 (H), RGF966 (L), or RGF966 (H) as shown in (G) with quantification data
shown in a box plot (H). Each box in the graph indicates the interquartile range (IQR). The horizontal line represents the median value. Box lower limit is the first
quantile (Q1) while the upper limit is the third quantile (Q3). The lower whisker is max(min(x)), Q1 – 1.5*IQR while the upper whisker is min(max(x)), Q3 + 1.5*IQR.
DMSO (n = 144) versus GDC (H) (n = 180): ***P = 2.23e-32, DMSO versus RGFP (L) (n = 233): ***P = 1.04e-36 and DMSO versus RGFP (H) (n = 83): ***P = 3.12e-35
were performed by Wilcoxon rank sum test with continuity correction. Scale bar, 100 lm.
I, J Mice with C4-2 xenograft tumors were treated with vehicle (DMSO), GDC0068 (H) (50 mg/kg), RGFP966 (L) (25 mg/kg), or RGFP966 (H) (50 mg/kg) 5 days a week
for three consecutive weeks (I). Images of tumors isolated at day 21 are shown in (J). Data are shown as means  SEM. DMSO (n = 7) versus GDC0068 (H) (n = 7):
***P = 4.18e-10, DMSO versus RGFP966 (L) (n = 7): ***P = 1.40e-09, GDC0068 (H) versus RGFP966 (H) (n = 7): *P = 0.0182, RGFP966 (L) versus RGFP966 (H):
*P = 0.0104 comparing the tumor volume at day 21 post-treatment by the unpaired two-tailed Student’s t-test.
K–M Representatives of organoids at day 5 post-treatment of GDC0068 (H), RGF966 (L), or RGF966 (H) are shown in (K) with quantification data of OD value at
490 nm in (L). The OD value was measured and quantified from three biological replicates. Data represent means  SEM; DMSO versus GDC0068 (H):
***P = 2.18e-05; DMSO versus RGFP966 (L): ***P = 1.43e-04, DMSO versus RGFP966 (H): ***P = 1.40e-08 were performed using the unpaired two-tailed Student’s
t-test. Based on the observed growth rate of untreated PTEN-deleted organoids, greater than 50% of organoids reach 30 lm in diameter at day 5. “30 lm” was set
as the cutoff value. The number of organoids with the diameter > 30 lm from at least five fields (each field contains at least 7 organoids) were counted and
analyzed from three biological replicates (M). Data are shown as means  SEM; DMSO versus GDC0068 (H): ***P = 8.02e-05; DMSO versus RGFP966 (L):
***P = 1.39e-04, DMSO versus RGFP966 (H): ***P = 2.96e-06 were performed by the unpaired two-tailed Student’s t-test. Scale bar, 100 lm.
Source data are available online for this figure.
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AR protein level (Fig 7F), providing a plausible explanation as to
why the cells were relatively resistant to GDC0068 treatment. In
contrast, we found that, in addition to inhibiting AKT signaling,
RGFP966 inhibited expression of AR and its downstream target
genes including NKX3.1, PSA, and TMPRSS2 in C4-2 cells (Figs 7F,
and EV5A and B). This is consistent with a previous finding showing
that depletion of HDAC3 by shRNA diminished AR mRNA level (Wels-
bie et al, 2009). To further clarify the contribution of AKT phosphory-
lation inhibition or AR reduction to the overall efficacy of RGFP966,
AR and constitutively active (myristoylated) AKT (CA-AKT) were
exogenously expressed in C4-2 cells and drug sensitivity was exam-
ined in these cells. Clonogenic survival assays showed that exogenous
expression of AR or CA-AKT alone only partially blocked RGFP966-
induced inhibition of C4-2 cell growth (Fig EV5C and D), suggesting
that both AKT inhibition and AR reduction are important for RGFP966
inhibition of cell growth. The 3D Matrigel culture further confirmed
the anti-cancer effect of the higher concentration of RGFP966 on C4-2
cell growth (Fig 7G and H). Studies with C4-2 xenograft model further
showed that a higher concentration of RGFP966 was efficient in
inhibiting tumor growth in mice (Fig 7I and J).
To further extend our findings from cell culture systems to more
clinically relevant models, a PTEN-deficient patient-derived orga-
noid line (Gao et al, 2014) was employed. In this model, we also
observed that the higher concentration of RGFP966 not only signifi-
cantly impaired the overall proliferation of organoids cultured in 3D
(Fig 7K and L), but also significantly decreased the size of organoids
(Fig 7M). Together, these data indicate that the HDAC3 inhibitor
blocks PTEN-mutated prostate cancer cell growth by targeting both
AKT and AR signaling.
Inhibition of HDAC3 suppresses SPOP-mutated prostate
cancer growth
Approximately 10% of prostate cancer patients harbor SPOP muta-
tions (Barbieri et al, 2012). In this subtype of prostate cancers, both
AKT and AR signaling are aberrantly activated (An et al, 2014; Geng
et al, 2014; Blattner et al, 2017; Zhang et al, 2017). Currently, strate-
gies for effectively treating this unique subclass of patients remain to
be explored. Given that inhibition of HDAC3 can target both AKT
and AR signaling pathways, we hypothesized that RGFP966 is an
effective agent to suppress the growth of SPOP-mutated tumors. To
mimic the scenario in patient samples where SPOP mutations
detected so far are heterozygous and almost mutually exclusive with
PTEN mutations or deletions, we introduced SPOP-mutant F133V, a
hotspot mutation (Barbieri et al, 2012), into a PTEN-positive 22Rv1
cell line in which AKT phosphorylation level is relatively low
(Fig 7A). Similar to the findings reported recently (An et al, 2014;
Blattner et al, 2017; Zhang et al, 2017), we observed that expression
of SPOP F133V elevated the level of phosphorylated AKT, S6K, and
4E-BP1 as well as that of the full-length AR, but had almost no effect
on AR splice variants (Fig 8A). However, following RGFP966 treat-
ment, phosphorylation of AKT and its downstream targets S6K and
4E-BP1 were significantly decreased in SPOP-F133V-expressing
22Rv1 cells (Fig 8A). Notably, the expression of both full-length AR
and variants was almost completely inhibited by RGFP966 in a dose-
dependent manner (Figs 8A and EV5B).
To investigate whether HDAC3 inhibitor alone enables to
suppress SPOP-mutant cell growth, both empty vector (EV)- and
SPOP-F133V-expressing 22Rv1 cells in 3D cultures were treated with
RGFP966. Similar to the results in C4-2 cells (Fig 7G), RGFP966
alone was efficient to inhibit growth of SPOP-F133V-expressing
22Rv1 cells (Fig 8B and C). The treatment also effectively inhibited
growth of patient-derived SPOP-mutated organoids (Fig 8D and E).
The inhibitory effect of RGFP966 was further confirmed by the
significant decrease in the size of organoids (Fig 8F). The IFC results
demonstrated that RGFP966 effectively inhibited both AR and AKT
signaling in these organoids (Fig 8G and H). Thus, our data suggest
that inhibition of HDAC3 effectively suppresses the growth of SPOP-
mutated prostate cancer cells by shutting down both AKT and AR
signaling pathways.
Discussion
AKT is abnormally activated in up to 70% of advanced prostate
cancers due to frequent deletion of PTEN or active mutations in
PI3K/AKT pathway genes (Taylor et al, 2010). Deregulation of PI3K/
PTEN pathway results in aberrant elevation of phosphatidylinositol
(3,4,5)-trisphosphate (PIP3) and subsequent phosphorylation of AKT
mediated by PDK1 and mTORC2. Besides phosphorylation, polyubiq-
uitination of lysine residues on AKT and membrane transportation is
also required for its activation (Yang et al, 2009). In contrast, AKT
phosphorylation can be suppressed by pan inhibitors of class I/II
HDACs (Chen et al, 2005a). A possible explanation of this observa-
tion is that pan inhibitor treatment results in increased histone
acetylation which promotes the expression of genes encoding such
proteins as PHLPP1, a protein phosphatase that decreases AKT
phosphorylation in chondrocytes (Bradley et al, 2013). However, we
provided evidence that inhibition of de novo protein synthesis by
CHX failed to have overt effect on class I/II HDACI-induced suppres-
sion of AKT phosphorylation in prostate cancer cells and the drug
effect appears to be an immediate event (30 min post-treatment).
These findings suggest that inhibition of AKT phosphorylation by
class I/II HDACIs is not primarily mediated by the genomic effect of
these HDACIs in the nucleus of prostate cancer cells. Class I/II
HDACI treatment studies also raise a very important question as to
which HDAC protein(s) mediate the effect on AKT phosphorylation.
Through unbiased shRNA screening, we demonstrated for the first
time that HDAC3 is the only member of the class I/II HDAC subfam-
ily that regulates AKT phosphorylation in C4-2 prostate cancer cells.
In support of our conclusion that inhibition of AKT phosphorylation
by class I/II HDACIs is unlikely mediated by their genomic effect in
the nucleus, HDAC3 is one of the few class I/II HDAC proteins that
are localized in the cytoplasm, plasma membrane, and the nucleus
(McKinsey et al, 2000; Yang et al, 2002).
Aberrantly activated AKT has long been recognized as an attrac-
tive therapeutic target. AKT inhibitors are currently being utilized
for clinical trials. In most scenarios, they exhibit optimal anti-cancer
activities only when combined with the other therapeutic agents
(Hirai et al, 2010; Pei et al, 2016). Particularly in prostate cancer,
one of the major hurdles is the existence of negative feedback
between AKT and AR signaling pathways, making a single blockage
of AKT signaling inefficient in the treatment of prostate cancer.
Therefore, based on the findings in this study and others, there are
several reasons that inhibition of HDAC3 might be an ideal target
for the treatment of prostate cancer.
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Figure 8. The HDAC3 inhibitor suppresses SPOP-mutated prostate cancer cell growth.
A 22Rv1 cells stably infected with SPOP F133V mutant lentivirus were treated with 3 lM of RGFP966 for 24 h and harvested for Western blot with the indicated
antibodies.
B, C Representative images of 3D Matrigel cultures 22Rv1 cells stably infected control or SPOP F133V lentivirus at day 5 post-treatment of RGF966 are shown in (B) with
the quantitative data in a box plot (C). The lentivirus transfection efficiency is at least 95% of total cells. In graph (C), the description for box plot is the same as the
figure legend in Fig 7H. Data are shown as means  SD. DMSO-Lenti-EV (n = 188) versus RGFP966-Lenti-EV (n = 139): ***P = 3.05e-11, DMSO-SPOP-F1333V
(n = 130) versus RGFP966-SPOP-F133V (n = 193): ***P = 2.85e-12 were performed by Wilcoxon rank sum test with continuity correction. Scale bar, 100 lm.
D–F Representatives of patient-derived SPOP-mutant organoids at day 5 post-treatment of DMSO or 3 lM of RGF966 are shown in (D) with the quantitative data of OD
value at 490 nm in (E). ***P = 1.43e-04 was performed using the unpaired two-tailed Student’s t-test. Based on the observed growth rate of untreated SPOP-
mutated organoids, greater than 50% of organoids reach 10 lm in diameter at day 5. “10 lm” was set as the cutoff value. The number of organoids with the
diameter > 10 lm) from at least five fields were counted and analyzed (F). Data are shown as means  SEM. ***P = 3.36e-05 was performed by the unpaired
two-tailed Student’s t-test. Scale bar, 100 lm.
G, H Patient-derived SPOP-mutant organoids were treated with vehicle (DMSO) or 3 lM of RGF966 for 5 days and harvested for IFC for phosphorylated AKT (S473) (G)
and AR (H). Scale bars, 50 lm.
Source data are available online for this figure.
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Firstly, a previous study has revealed that increased expression
of HDACs and activation of PI3K/AKT-mTORC1 pathway
commonly occur in prostate cancer (Ellis et al, 2013), suggesting
that both are highly relevant to prostate cancer. In this study, we
reveal a positive correlation between HDAC3 expression and AKT
phosphorylation at the molecular level, a spontaneous prostate
cancer mouse model, tumor-derived organoids, and patient speci-
mens. Indeed, one recently published paper demonstrated that only
a combined treatment with pan class I/II HDACIs (e.g., LBH-589)
and PI3Ki (BKM-120) can effectively inhibit the growth of aggres-
sive MYC-driven medulloblastoma in mice (Tzivion et al, 2011).
Mechanically, it has been shown that pan HDACIs upregulate
FoxO1 mRNA and protein levels, while PI3Ki induces nuclear accu-
mulation of FoxO1 protein. Different from the strategy used for
brain tumor treatment, we demonstrated in the present study that
both genetic deletion of or pharmacological inhibition of HDAC3
alone is sufficient to block prostate cancer cell growth in vitro and
in vivo, highlighting the value of single-agent targeting of HDAC3
for prostate cancer treatment.
Secondly, HDACIs have been associated with the interruption of
the AR pathway (Welsbie et al, 2009), which makes HDACIs some-
how efficient for the treatment of prostate cancer. Given that AKT
signaling and AR are two critical pathways in driving the pathogene-
sis of prostate cancer, the synergetic inhibition of these two path-
ways might pose a huge threat on the progression of prostate
cancer. Indeed, the pharmacological inhibition of both pathways
has led to a complete prostate tumor regression in a Pten-deficient
murine prostate cancer model and in human prostate cancer xeno-
grafts (Carver et al, 2011). Interestingly, unlike the FDA-approved
antiandrogen enzalutamide, which suppresses AR signaling path-
way while inducing AR mRNA expression, we observed that
HDAC3-specific inhibitor RGFP966 blocked expression of both AR
mRNA and its downstream target genes including NKX3.1, PSA, and
TMPRSS2 (Fig EV5D). Most strikingly, RGFP966 inhibits the expres-
sion of both full-length and variant AR proteins. Our data suggest
that dual inhibition of AKT and AR signaling in prostate cancer,
especially in those with genetic alterations such as PTEN loss, can
be achieved by single administration of HDAC3-specific inhibitor.
Thirdly, SPOP is the most frequently mutated gene in primary
prostate cancer (Barbieri et al, 2012; Cancer Genome Atlas Research
Network, 2015). Intriguingly, all the mutations in SPOP gene
detected in prostate cancer thus far affect the binding of SPOP with
its substrates. Previous biochemical studies identified that AR and
transcription co-regulators including SRC-3, TRIM24, ERG, and
BRD4 are degradation targets of SPOP and that mutations in SPOP
result in aberrant elevation of these proteins and increased activities
of AR (Geng et al, 2013, 2014; An et al, 2014, 2015; Theurillat et al,
2014; Groner et al, 2016; Blattner et al, 2017; Zhang et al, 2017).
Notably, ectopic expression of F133V (a hotspot mutation of SPOP)
in human prostate cancer cells or knock-in of this mutant in the
mouse prostate results in an abnormal activation of AKT-mTORC1
signaling (Blattner et al, 2017; Zhang et al, 2017). Thus, SPOP muta-
tions uncouple the negative feedback between AKT and AR signal-
ing pathways and drive prostate tumorigenesis and progression
(Blattner et al, 2017). We provided evidence that treatment with the
HDAC3-specific inhibitor RGFP966 not only effectively decreased
AKT activities and the expression of full-length AR and splicing vari-
ants in SPOP-mutant-expressing prostate cancer cell lines and
patient-derived organoids, but also inhibited the growth of SPOP-
mutant prostate cancer cells in 2D and 3D cultures. These findings
stress that HDAC3 is also a viable therapeutic target for SPOP-
mutated prostate cancer.
In summary, our findings have demonstrated for the first time
that the cytoplasmic (non-genomic) activity of HDAC3 is required
for AKT phosphorylation and AR upregulation in prostate cancer
cells. Treatment of prostate cancer cells with HDAC3-specific inhi-
bitor not only inhibits AKT-mTORC1 signaling, but also suppresses
expression of AR and its downstream target genes. In addition, the
promising findings in the pre-clinical models (Matthews et al, 2015;
Jiang et al, 2017) suggest that HDAC3 inhibition might lead to
appropriate cancer trials in the future. Given that both AKT and AR
signaling are aberrantly activated in prostate cancers, especially
those with PTEN deletions or SPOP mutations, dual inhibition of
AKT and AR pathways by administrating the single-agent HDAC3
inhibitor makes HDAC3 inhibition an attractive strategy for prostate
cancer treatment in the clinic.
Materials and Methods
Plasmids and reagents
The mammalian expression vectors for HA-tagged ubiquitin (HA-
Ub), Myc-AKT, Flag-HDAC3 were all purchased from Addgene.
HDAC3 and AKT mutant expression vectors were generated using
the KOD-Plus Mutagenesis Kit (Toyobo). Insulin-growth factor 1
(IGF-1) and epidermal growth factor (EGF), cycloheximide (CHX)
and HDAC inhibitors, including trichostatin A (TSA), suberoy-
lanilide hydroxamic acid (SAHA), LBH589, GDC0068, RGFP966, and
tubastatin A (Tuba) were purchased from Sigma-Aldrich. The anti-
bodies used are as follows: Anti-ERK 2 (D-2) (sc-1647), AKT (sc-
5298), AR (H-280) (sc-13062), and anti-Myc tag from Santa Cruz
Biotechnology; Anti-HA from Covance; Flag-M2 (F-3165) from
Sigma; Cleaved caspase-3 (Asp175) (D3E9) (9579S), Tubulin (9F3)
(2128S), 4E-BP1 (53H11) (9644S), Phospho-4E-BP1 (2855S), P70 S6
Kinase (9202S), Phospho-S6K (T389) (4858S), Phospho-AKT-Thr308
(9275S), Phospho-AKT-Ser473 (9271S) and PTEN (9559S), total
AKT antibody (9272S, recognizing three AKT isoforms) from Cell
Signaling Technology; HDAC3 (ab16047), FBP1 (ab109732), and
Ki67 (ab15580) from Abcam. Anti-acetyl-lysine antibody from
Upstate; E-cadherin (610181) from BD Biosciences; SPOP (16750-1-
AP) from Proteintech Group Inc. For Western blots, all the antibod-
ies were diluted 1 in 1,000, whereas for IFC, the antibodies were
diluted 1 in 500. Matrigel Basement membrane Matrix (# 354248)
was purchased from Corning Life Sciences. The secondary flores-
cence antibodies (Alexa Fluor 488 and Alexa Fluor 594) were
purchased from Thermo Fisher.
Cell lines, cell culture, and 3D culture
The immortalized human embryonic kidney cell line 293T was
purchased from ATCC (Manassas, VA) and cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10% FBS.
The prostate cancer cell lines PC-3, 22Rv1, VCaP, and LNCaP were
purchased from ATCC (Manassas, VA). C4-2 cells were acquired
from UroCorporation. All prostate cancer cells applied in this study
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were cultured in 10% FBS (Hyclone) in RPMI 1640 medium (Invitro-
gen) supplemented with penicillin and streptomycin. The cultured
cells were maintained in a 37°C humidified incubator supplied with
5% CO2.
For three-dimensional (3D) cultures, 2 × 104 of C4-2 or 22Rv1
cells were resuspended in 250 ll plain medium and seeded on the
top of a thin layer of Matrigel in a 24-well plate. After 30 min, when
the cells were settled down, they were covered with another layer of
10% Matrigel diluted with DMEM/F12 medium. The medium was
changed with 500 ll of fresh and warm DMEM/F12 plus 5% FBS
medium every 2–3 days.
Real-time PCR
Total RNAs were extracted with TRIzol (Invitrogen) and reverse
transcribed into cDNA with SuperScript III First-Strand Synthesis
System (Promega). Quantitative PCR was done in the iQ thermal
cycler (Bio-Rad) using the iQ SYBR Green Supermix (Bio-Rad) and
in triplicate. The DCT was calculated by normalizing the threshold
difference of certain gene with glyceraldehyde-3-phosphate dehydro-
genase (GAPDH).
Mouse maintenance and genotyping
Hdac3 conditional knockout (Hdac3L/L) mice were reported previ-
ously (Bhaskara et al, 2008) and kindly provided by Dr. Jennifer
Westendorf at Mayo Clinic. Pten conditional knockout (PtenL/L)
mice were originally generated in the laboratory of Dr. Hong Wu at
University of California Los Angeles (Wang et al, 2003) and
purchased from the Jackson Laboratory. The Pb-Cre4 transgenic
mice were generated originally in the laboratory of Dr. Pradip Roy-
Burman, at the University of Southern California (Wu et al, 2001)
and acquired from the National Cancer Institute (NCI) Mouse Repos-
itory. The cohorts of Hdac3pc/; Ptenpc/, Hdac3L/L; Cre;PtenL/L,
Hdac3pc/ (“wild-type”), and Ptenpc/ male mice were generated
from Hdac3pc+/; Ptenpc+/ males and Hdac3L/+; PtenL/+ females,
which were obtained by crossbreeding Pb-Cre4 males with Hdac3L/L
and PtenL/L females. All mice were maintained under standard
conditions of feeding, light, and temperature with free access to food
and water. All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee (IACUC) at Mayo Clinic.
Genotyping of wild-type and conditional alleles of Pten genes, as well
as the Cre transgene, was performed according to previously described
PCR protocols (Wu et al, 2001; Lesche et al, 2002). The Hdac3
genotyping primer sequences are provided in Appendix Table S1.
Transfection of expression vectors, RNA interference (siRNA),
and shRNA
Transfections were performed either by electroporation using an
Electro Square Porator ECM 830 (BTX) (Chen et al, 2010) or by
Lipofectamine 2000 (Invitrogen). Approximately 75–90% transfec-
tion efficiencies were routinely achieved. The siRNA constructs
were purchased from GE Dharmacon. The transfection for siRNA
was performed using Lipofectamine RNAiMAX (Thermo Fisher)
according to the manufacturer’s instruction. The siRNA sequence
information is provided in Appendix Table S2. All shRNA constructs
were purchased from Sigma and transfected with lentivirus.
Western blot and immunoprecipitation (IP)
Western blotting was performed as described previously (Chen
et al, 2010). Antibodies used for Western blotting were diluted at
1:1,000 to 1:2,000. The IP was carried out using an IP kit (Roche
Applied Science) as described previously (Huang et al, 2006).
Immunofluorescent cytochemistry and immunohistochemistry (IHC)
Immunohistochemistry and IFC were performed as previously
described (Xu et al, 2014). The sections for IHC were cut at 4 lm
thickness. Antigen retrieval was conducted via heat-induced epitope
retrieval, with 10 mM sodium citrate buffer (pH 6.0) for all antibod-
ies used in this study. Antibodies for HDAC3, PTEN, and P-AKT
(Ser473) were incubated at 4°C overnight. Color was developed with
SignalStain DAB Substrate Kit.
Microscopic observations and analysis
Immunohistochemistry and H&E staining were observed with a
Leica light microscope (10×, 20×, and 40×). Cell growth of 3D
Matrigel culture was recorded using Leica microscope at day 7, and
the diameter of 3D culture was analyzed with Leica software—LAS
EZ. IFC staining images were obtained via a Zeiss LSM 780 confocal
microscope. Staining intensity and staining percentage for each
tissue were graded using set criteria. Staining intensity was graded
into four categories: 0, 1, 2, and 3. Specifically, 0 represents no staining,
1 low staining (staining obvious only at ×400), 2 medium staining
(staining obvious at ×100 but not ×40), and 3 strong staining (stain-
ing obvious at ×40). Stain percentage was graded 1 for 0–33%
positive cells, 2 for 34–66%, and 3 for 67–100%. The final SI score
for each staining was obtained by multiplying values obtained from
staining percentage and intensity and used for correlation analysis.
Clonogenic survival
The procedure was conducted by following a previous report
(Franken et al, 2006). Briefly, an appropriate number of cells for dif-
ferent dosages of drugs were plated onto 6-well plate. At the follow-
ing day, cells were treated with DMSO, GDC0068, RGFP966, and the
combination of GDC0068 and RGFP966. Four days post-treatment,
cells were cultured with fresh medium without drugs for another
8 days. Around 12 days later, colonies were fixed with acetic acid:
methanol (1:7) for 30 min and stained with (0.5% w/v) crystal
violet for 1 h. Colonies were gently washed with running tap water.
Colonies with more than 50 cells were counted, and the number of
colonies was normalized to untreated group. The linear regression
was applied to generate the survival curve.
Patient-derived organoid culture
A PTEN-deleted and a SPOP-mutant (G131R) organoid lines were
kindly provided from Dr. Chen laboratory in Memorial Sloan-
Kettering Cancer. The detailed extraction and culture procedures
were referred to two published papers (Gao et al, 2014; Drost et al,
2016). Briefly, the organoids were seeded onto a thin layer of
Matrigel and passaged every 3–4 days. The recipe of culture
medium can be seen in the previous report (Drost et al, 2016).
ª 2018 The Authors EMBO Molecular Medicine 10: e8478 | 2018 17 of 20
Yuqian Yan et al AKT and AR inhibition by targeting HDAC3 EMBO Molecular Medicine
Informed consent was obtained from all subjects and that the exper-
iments conformed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human Services
Belmont Report.
Mouse xenograft and tumor analysis
The 6-week-old NOD-SCID IL-2-receptor gamma null (NSG) male
mice were generated in house and randomly divided into different
experimental groups as indicated. Mice were injected with 1 × 107
of C4-2 cells in 100 ll of Matrigel matrix (BD Bioscience) in the left
flank. GDC-0068 was formulated in 0.5% methylcellulose/0.2%
Tween-80 (MCT) and administered via oral gavage daily at
50 mg/kg (Lin et al, 2013), while RGFP966 was dissolved in DMSO
and diluted in a vehicle of 30% (wt/vol) hydroxypropyl-b-cyclodex-
trin and 100 mM sodium acetate (pH 5.4) as reported previously
(Malvaez et al, 2013) and administrated subcutaneous injection
(s.c) at 25 mg/kg (L) or 50 mg/kg (H). The drug administration was
5 days a week for 21 consecutive days. After implantation of tumor
cells into mice, tumors were monitored until they reached mean
tumor volumes of 180–350 mm3 and distributed into four groups (7
mice/group). Tumor growth was measured externally by caliper
twice a week. The protocol for conducting this mouse xenograft
experiment was approved by Mayo Clinic IACUC.
Generation of graphs and statistical analysis
Graphs were generated by using Graphpad Prism 5 project (Graph-
pad Software Inc, CA, USA) or Microsoft Office Excel 2010. All
numerical data are presented as mean  SEM or mean  SD as
required. The survival percentage was compared by Chi-square
tests. Differences between groups were compared by unpaired
t-tests or Wilcoxon rank sum test with continuity correction by R
software version 2.15.0 (http://www.r-project.org). The following
symbols were used to denote statistical significance: *P < 0.05,
**P < 0.01, ***P < 0.001.
Expanded View for this article is available online.
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